Oncological Outcomes in Bacillus Calmette-Guérin–naïve High-risk Non–muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future Perspectives
Mattia Longoni(Vita-Salute San Raffaele University), Marco Moschini(Vita-Salute San Raffaele University), Évanguelos Xylinas(NewYork–Presbyterian Hospital), Pietro Scilipoti(Vita-Salute San Raffaele University), David D‘Andrea(Medical University of Vienna), Ekaterina Laukhtina(Comprehensive Cancer Center Vienna), Paolo Gontero(Fondazione Ricerca Molinette), Aleksander Ślusarczyk(Medical University of Warsaw), Luca Afferi(Universitat Autònoma de Barcelona), Keiichiro Mori(Jikei University School of Medicine), Benjamin Pradère, Andrea Gallioli(Universitat Autònoma de Barcelona), Simone Albisinni(University of Rome Tor Vergata), José Daniel Subiela(Universidad de Alcalá), Renate Pichler(Innsbruck Medical University), Andrea Necchi(Vita-Salute San Raffaele University), Piotr Radziszewski(Medical University of Warsaw), Andrea Mari(Azienda Ospedaliero-Universitaria Careggi), Francesco Del Giudice(Sapienza University of Rome), Morgan Rouprêt(Sorbonne Université), Francesco Soria, Francesco Montorsi(Vita-Salute San Raffaele University), Alberto Briganti(Vita-Salute San Raffaele University), Laura S. Mertens(Oncode Institute), Shahrokh F. Shariat(Cornell University), Wojciech Krajewski(Wroclaw Medical University)
Cited by 43
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k